NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • huPBMC-NOG-F
    NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
  • huPBMC-NOG-M
    NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac
  • huPBMC-NOG is a model for investigation of adult/mature cell populations.
  • This model permits the assessment of effector and memory T cells.
  • PBMC engrafted mice are optimally suited for studies immediately following engraftment as Graft vs. Host Disease (GvHD) limiting survival time to 4-6 weeks. In addition, the GvHD response can be used as a screening system for T cell modulating drugs, with readouts including body weight and clinical condition, liver injury and immune cell infiltration into organs.
  • See Søndergaard et al. and Cox et al. for description of the GvHD model and its use in drug target validation.
  • Inquire about options such as irradiation, PBMCs of specific donor HLA types or patient-derived PBMCs.


huPBMC-NOG mice are produced upon order and delivered within one week of injections.





huPBMC-NOG mouse chart #1
Chart #1: Human CD45+ cells were enumerated by flow cytometry at daily intervals follow PBMC engraftment. Significant engraftment was observed after 14 days. The majority of human CD45+ cells are CD3+ T cells.

huPBMC-NOG mouse chart #2
Chart #2: Irradiation exacerbates GvHD in PBMC engrafted NOG mice. Survival curves for PBMC engrafted NOG mice at increasing doses of radiation with, or without pre-treatment with anti-TNFa blocking antibody.
Download documentation that describes huPBMC-NOG production practices, health testing and health designation, recommended care and Conditions of Use for huPBMC-NOG.
Base pricing is $400 / €320 per mouse. The typical lead time for a cohort of standard huPBMC-NOG is three weeks. Please inquire for more details or to place your order.